Myeloma Combo With ‘Unprecedented’ Effect Wins FDA Approval

(MedPage Today) — A promising combination for multiple myeloma received FDA approval as a second-line therapy.
The approval of teclistamab (Tecvayli) plus daratumumab hyaluronidase (Darzalex Faspro) stipulates use in patients who have received…